Turner syndrome and growth hormone therapy: a review on growth response
© Selveindran et al; licensee BioMed Central Ltd. 2015
Published: 28 April 2015
Turner syndrome (TS) is a sex-chromosome abnormality in females resulting from partial or complete absence of one of the X chromosomes . One of the main features of TS is short stature. Final height in short girls with TS improves with growth hormone treatment . The aim of this study was to assess the effectiveness of growth hormone therapy in a cohort of Malaysian patients with TS.
Data from the electronic medical records of 20 patients with TS treated with growth hormone in Putrajaya Hospital, Malaysia from the year 2005 to 2014 was analysed.
The mean age of initiation of therapy was 11.5 ± 3.4 and 55.0% were started after the age of 12 years. The mean height standard deviation score (SDS) increased from -3.84 (±0.94) SD at study entry to -3.47 (±0.97) SD at the end of the first year. This improvement was seen with subsequent year of treatment, though the degree of change in height SDS reduced with time. Age of initiation of therapy had a bearing on treatment response as those who had received growth hormone at an earlier age experienced better growth response. 75.0% of patients who achieved final height were able to achieve the final height within the target height. Of the patients who achieved final height, mean age of puberty was 16 ± 1.5 years and mean height SDS at onset of puberty was -3.3SD. There were no reported adverse events.
Growth hormone therapy improved growth profile of Malaysian children with TS and the importance of early initiation of therapy is demonstrated in this study.
- Ross J, Lee PA, Gut R, Germak J: Impact of age and duration of growth hormone therapy in children with growth hormone therapy in children with Turner syndrome. Horm Res Pediatr. 2011, 76: 392-399. 10.1159/000333073.View ArticleGoogle Scholar
- The Canadian Growth Hormone Advisory Committee: Impact on growth hormone supplementation on adult height in Turner syndrome : results of the Canadian Randomized Controlled Trial. J Clin Endocrinol Metab. 2005, 90: 3360-3366.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.